Alkeon Capital Management LLC Has $40.02 Million Stock Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Alkeon Capital Management LLC lifted its position in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 2.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,904,096 shares of the company’s stock after buying an additional 100,000 shares during the quarter. Alkeon Capital Management LLC owned about 5.53% of ORIC Pharmaceuticals worth $40,017,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its holdings in ORIC Pharmaceuticals by 140.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock valued at $21,543,000 after purchasing an additional 915,175 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of ORIC Pharmaceuticals by 62.0% in the second quarter. Bank of New York Mellon Corp now owns 186,484 shares of the company’s stock valued at $1,318,000 after buying an additional 71,394 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new stake in ORIC Pharmaceuticals during the second quarter worth approximately $724,000. Creative Planning bought a new position in ORIC Pharmaceuticals during the 3rd quarter worth $116,000. Finally, Monaco Asset Management SAM increased its stake in ORIC Pharmaceuticals by 132.0% during the 2nd quarter. Monaco Asset Management SAM now owns 301,650 shares of the company’s stock worth $2,133,000 after acquiring an additional 171,650 shares during the period. Institutional investors own 95.05% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. Oppenheimer reduced their target price on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating on the stock in a report on Tuesday, August 13th. Wells Fargo & Company started coverage on shares of ORIC Pharmaceuticals in a research note on Thursday, October 31st. They set an “overweight” rating and a $20.00 price objective on the stock. Wedbush restated an “outperform” rating and issued a $20.00 target price on shares of ORIC Pharmaceuticals in a research report on Tuesday, November 12th. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, November 4th. Finally, Stifel Nicolaus initiated coverage on shares of ORIC Pharmaceuticals in a research note on Friday, September 6th. They issued a “buy” rating and a $20.00 price objective on the stock. Eight analysts have rated the stock with a buy rating, According to MarketBeat, ORIC Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $18.29.

ORIC Pharmaceuticals Stock Up 1.7 %

Shares of ORIC Pharmaceuticals stock opened at $9.97 on Friday. The firm’s 50 day moving average is $9.57 and its 200 day moving average is $9.33. ORIC Pharmaceuticals, Inc. has a 1 year low of $6.33 and a 1 year high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Tuesday, November 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.01). As a group, analysts predict that ORIC Pharmaceuticals, Inc. will post -1.84 earnings per share for the current year.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.